- Home
- STXS vs ANTX Comparison
STXS vs ANTX Comparison
Compare STXS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STXS | ANTX |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.7M | 170.7M |
| IPO Year | 2004 | 2022 |
Fundamental Metrics
Financial Performance| Metric | STXS | ANTX |
|---|---|---|
| Price | $1.79 | $4.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $4.00 | $2.00 |
| AVG Volume (30 Days) | ★ 469.6K | 383.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,346,617.00 | N/A |
| Revenue This Year | $28.22 | N/A |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.59 | $1.00 |
| 52 Week High | $3.59 | $6.91 |
Technical Indicators
Market Signals| Indicator | STXS | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 44.46 |
| Support Level | $1.74 | $3.82 |
| Resistance Level | $1.99 | $5.21 |
| Average True Range (ATR) | 0.10 | 0.40 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 51.28 | 0.91 |
Price Performance
Historical ComparisonAbout STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.